Eye-movement biomarkers may flag Parkinson’s decline earlier

Neuralight’s eye-movement biomarkers may predict declines in daily functioning in people with Parkinson’s disease before those changes can be detected by conventional clinical assessments, new clinical study data suggest. The PALOMA study (NCT05862649), which involved hundreds of adults at clinical sites in the U.S. and Europe, previously produced data that Neuralight said showed the biomarkers…